Insiders · ERNA

Peter Cicala

Director at Ernexa Therapeutics Inc. (ERNA) since February 2024

Peter Cicala has filed 4 insider reports with the SEC since February 2024, as director at Ernexa Therapeutics Inc. (ERNA). The latest filing, on September 2, 2026, reports grant or award at Ernexa Therapeutics Inc. (ERNA).

Filings
4
Companies
1
Bought on market
None
Sold on market
None

Companies where Peter Cicala is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Ernexa Therapeutics Inc. logo
ERNA
Ernexa Therapeutics Inc.
Directorsince February 2024$1.63Sep 2, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Peter Cicala with

Other insiders at the same companies

Questions about Peter Cicala

What is Peter Cicala's role at Ernexa Therapeutics Inc.?
Peter Cicala reports to the SEC as director at Ernexa Therapeutics Inc. (ERNA), according to the latest filing on September 2, 2026.
Has Peter Cicala bought or sold stock recently?
No open-market purchases or sales by Peter Cicala are on file. The filings report grant or award.
How do I get alerts when Peter Cicala files?
Follow Peter Cicala on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Peter Cicala filed 1 time in the last 90 days.

From SEC Forms 3, 4, 5 and 144 filed by Peter Cicala (SEC CIK 0002011534). Totals count each trade once, skipping amendments whose original is on file, from Feb 16, 2024 on. View on SEC EDGAR · Get this as JSON